Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion

FILE PHOTO: Attendees walk past the Merck logo at the BIO International Convention 2026, a meeting of pharmaceutical and biotechnology leaders in San Diego, California, U.S. June 23, 2026.

FILE PHOTO: Attendees walk past the Merck logo at the BIO International Convention 2026, a meeting of pharmaceutical and biotechnology leaders in San Diego, California, U.S. June 23, 2026. (REUTERS/Mike Blake/File Photo)


1 photo
Save Story

Estimated read time: 1-2 minutes

Sept 28 — Merck said on Monday it would pay up ​to $2.13 billion under a global licensing deal with China's SciBrunch Therapeutics for rights to develop, ‌manufacture and sell an experimental cancer treatment.

The deal underscores Merck's efforts to ⁠broaden its cancer drug ​pipeline as it prepares ⁠for patent expirations on Keytruda, its top-selling immunotherapy, ‌later this decade.

• ‌The deal, which has closed, gives Merck access ⁠to SPR2015, an oral ⁠drug candidate targeting KRAS G12D, one of the most common cancer-driving mutations found in pancreatic, colorectal and lung cancers.

• SciBrunch will receive an upfront payment of $400 million and is eligible for up to $1.73 ‌billion in potential milestone payments, the ​companies said.

• Merck said the transaction will result in a pre-tax charge of $400 million, or about 13 cents per share, in its third-quarter 2026 results.

• Scotiabank analyst Louise Chen said Merck has visibility into more than $70 billion in commercial opportunity by ​the mid-2030s, more than double Wall Street's estimate of ‌about $33 billion for ‌Keytruda's ⁠peak 2028 revenue.

• SPR2015 is in preclinical development and has not yet entered human testing.

• Preclinical data presented earlier this year showed the drug reduced tumor ‌growth in laboratory and ​animal models of KRAS G12D-mutant ‌cancers, the companies ⁠said.

(Reporting by ​Sahil Pandey in Bengaluru; Editing by Tasim Zahid and ​Shreya Biswas)

Photos

Most recent Lifestyle stories

Related topics

STAY IN THE KNOW

Get informative articles and interesting stories delivered to your inbox weekly. Subscribe to the KSL.com Trending 5.
By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Notice.
Newsletter Signup

KSL Weather Forecast

KSL Weather Forecast
Play button